Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452214 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
A Phase 1 study of Carcinoma, Non-Small Cell Lung and Head and Neck Squamous Cell Carcinoma, sponsored by Cantargia AB.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 3
- Study locations
NCT04452214: Completed Phase 1 study of Carcinoma, Non-Small Cell Lung and Head and Neck Squamous Cell Carcinoma, sponsored by Cantargia AB.
NCT04452214 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Head and Neck Squamous Cell Carcinoma that has completed, run by Cantargia AB. The registered enrollment target is 19 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04452214, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Head and Neck Squamous Cell Carcinoma, has completed, sponsored by Cantargia AB.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establish a recommended dose of CAN04 in combination with the standard dose of pembrolizumab (Part 1), and in combination with pembrolizumab standard dose, and Standard of Care carboplatin and pemetrexed (Part 2 - subjects with stage IV, non-squamous metastatic NSCLC). CAN04, pembrolizumab. carboplatin and pemetrexed will be administered intravenously.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG CAN04
Study Locations (3)
Colorado
- University of Colorado Cancer Center - Aurora
Florida
- Florida Cancer Specialists & Research Institute - Lake Mary
Pennsylvania
- Hospital of The University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-09-24 |
| Est. Completion | 2023-06-28 |
| Phase | Phase 1 |
What the finished NCT04452214 record still lists
NCT04452214 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (94% lower).
The record links to 4 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT04452214 reports a single indexed study location in Colorado, Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04452214 about?
NCT04452214 is a clinical study titled "A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors". This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establis...
What is the current status of trial NCT04452214?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2020-09-24. Estimated completion is 2023-06-28.
What conditions does trial NCT04452214 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Malignant Melanoma.
What interventions are being tested in trial NCT04452214?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), CAN04 (DRUG).
Who is sponsoring clinical trial NCT04452214?
This trial is sponsored by Cantargia AB, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04452214 being conducted?
This trial has 3 study locations across Colorado, Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04452214's enrollment target sits among peer trials
19 118th of 130 higher than 12 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI